Application | Comment | Organism |
---|---|---|
medicine | the expression level and properties of N-terminal 86 amino-acid isoform variant of sphingosine kinase 1, SK1b, in prostate cancer cells reduce its sensitivity to proteasomal degradation induced by 2-(4-hydroxyanilino)-4-(4-chlorophenyl)thiazole in comparison to isoform SK1a. The reduced sensitivity of SK1b to proteasomal degradation in response to 2-(4-hydroxyanilino)-4-(4-chlorophenyl)thiazole results in specific changes in ceramide and S1P levels that lead to apoptosis of androgen-sensitive but not androgen-independent LNCaP prostate cancer cells | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(S)-FTY720 vinylphosphonate | uncompetitive with sphingosine and is a mixed inhibitor with respect to ATP | Homo sapiens | |
2-(4-hydroxyanilino)-4-(4-chlorophenyl)thiazole | i.e. SKi, or SKI-II. Mixed inhibitor of sphingosine and ATP binding. N-terminal 86 amino-acid isoform variant SK1b shows reduced sensitivity to proteasomal degradation induced by 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole in comparison to isoform SK1a | Homo sapiens | |
FTY720 | i.e. fingolimod, competitive with sphingosine and uncompetitive with ATP | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q9NYA1 | enzyme is expressed as isoform SK1a of 42.5 kDa, and isoform SK1b, a 51 kDa protein identical to SK1a, but with an 86 amino acid N-terminal extension | - |